Advertisement
Advertisement
GRAL
GRAIL, Inc. Common Stock
45.67
USDSponsored
-1.89
-3.98%
Apr 10, 15:59 UTC -4
Closed
After-Market
45.58
-0.09
-0.19%
GRAL Earnings Reports
Positive Surprise Ratio
GRAL beat 5 of 5 last estimates.
100%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
$39.95M
/-$2.82
Implied change from Q4 25 (Revenue/ EPS)
-8.37%
/+15.57%
Implied change from Q1 25 (Revenue/ EPS)
+25.48%
/-8.74%
GRAIL, Inc. Common Stock earnings per share and revenue
On Feb 19, 2026, GRAL reported earnings of -2.44 USD per share (EPS) for Q4 25, beating the estimate of -2.76 USD, resulting in a 11.60% surprise. Revenue reached 43.60 million, compared to an expected 44.55 million, with a -2.15% difference. The market reacted with a -50.55% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of -2.82 USD, with revenue projected to reach 39.95 million USD, implying an increase of 15.57% EPS, and decrease of -8.37% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
MiNK Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.83
Actual
-$0.55
Surprise
+33.64%
Kairos Pharma, Ltd.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.07
Surprise
-28.68%
Imunon, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.19
Actual
-$1.99
Surprise
-66.18%
Soligenix, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.57
Actual
-$0.28
Surprise
+50.98%
Cadrenal Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.18
Actual
-$1.43
Surprise
-20.34%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$12.24
Actual
-$8.00
Surprise
+34.64%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
CNS Pharmaceuticals, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$5.19
Actual
-$10.15
Surprise
-95.50%
FAQ
What were GRAIL, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, GRAIL, Inc. Common Stock reported EPS of -$2.44, beating estimates by 11.6%, and revenue of $43.60M, -2.15% below expectations.
How did the market react to GRAIL, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -50.55%, changed from $101.53 before the earnings release to $50.21 the day after.
When is GRAIL, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for GRAIL, Inc. Common Stock's next earnings report?
Based on 6
analysts, GRAIL, Inc. Common Stock is expected to report EPS of -$2.82 and revenue of $39.95M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement